cAMP-dependent protein kinase inhibitor alpha (PKI-alpha)

cAMP-dependent protein kinase inhibitor alpha is a small cytoplasmic protein encoded by the PKIA gene, primarily known as an endogenous, extremely potent competitive inhibitor of protein kinase A (PKA) catalytic activity. It binds to and inhibits both C alpha and C beta catalytic subunits of PKA following cAMP-induced activation and dissociation of PKA regulatory chains. The protein plays a key role in negatively regulating cAMP/PKA signaling pathways and thereby modulating various processes such as gene transcription, cell growth, and metabolism[3][4][5][9]. PKI-alpha is not itself a therapeutic drug target, but PKA signaling (its target) is of interest for therapeutic intervention in various pathologies, particularly cancer, though drugs targeting PKI-alpha directly are not in clinical use[2][3][4][9]. Caveats/limitations: - PKI-alpha is an *endogenous protein inhibitor* of PKA, not a commonly pursued direct drug target. - There are currently *no approved drugs* or prominent clinical agents that directly target PKI-alpha[4][9]. - Its main function is regulatory, not catalytic; thus, it is not a classic receptor, enzyme, transporter, etc., but fits as an "enzyme inhibitor". - Disease connections are limited and indirect; research mainly focuses on its role in regulatory pathways, not as a disease driver or biomarker[9].

Other names

PKI-alphaPRKACN1 (obsolete)Protein kinase inhibitor alphacAMP-dependent protein kinase inhibitor, muscle/brain isoformPKIA (gene name)

Competitive inhibition of the catalytic subunit of cAMP-dependent protein kinase (PKA); Direct protein–protein interaction blocking kinase activity